Euretos presentation ACS
-
Upload
albertmons -
Category
Health & Medicine
-
view
218 -
download
2
Transcript of Euretos presentation ACS
![Page 1: Euretos presentation ACS](https://reader036.fdocuments.us/reader036/viewer/2022062406/55baaa87bb61eb744f8b4681/html5/thumbnails/1.jpg)
Beyond Text Mining: BRAIN
August 11th, 2014/ACS
![Page 2: Euretos presentation ACS](https://reader036.fdocuments.us/reader036/viewer/2022062406/55baaa87bb61eb744f8b4681/html5/thumbnails/2.jpg)
2
Market Drivers
Euretos
BRAIN
Use cases
Close
Topics
![Page 3: Euretos presentation ACS](https://reader036.fdocuments.us/reader036/viewer/2022062406/55baaa87bb61eb744f8b4681/html5/thumbnails/3.jpg)
The Data Tsunami
Datarrhoeia
Standards?
Needle Transport
DIY Data
Key drivers
3Copyright Euretos b.v. 2014
![Page 4: Euretos presentation ACS](https://reader036.fdocuments.us/reader036/viewer/2022062406/55baaa87bb61eb744f8b4681/html5/thumbnails/4.jpg)
4
* 2013: Ann Winblad legendary investor and senior partner at Hummer-Winblad
“Data is just like crude. It’s valuable, but if unrefined it cannot
really be used. It has to be changed into gas,
plastic, chemicals, etc., to create a valuable
entity that drives profitable activity.”
Data: The new oil
![Page 5: Euretos presentation ACS](https://reader036.fdocuments.us/reader036/viewer/2022062406/55baaa87bb61eb744f8b4681/html5/thumbnails/5.jpg)
Is anyone really ‘doing it’?
5Copyright Euretos b.v. 2014
![Page 6: Euretos presentation ACS](https://reader036.fdocuments.us/reader036/viewer/2022062406/55baaa87bb61eb744f8b4681/html5/thumbnails/6.jpg)
Life sciences – the perfect storm?
Phenome
Metabolome
Transciptome
Proteome
Genome
The easy ‘low hanging fruit’ medical discoveries have been madeNew ‘higher hanging fruit’ research is orders of magnitude more complexDrowning in data
1.5 new article published every minuteMassive multi-omics output data (genome data alone doubles per 8 months)
Lost in dataMany databases are consulted dailyEach only have a fragment of the puzzleEach have specific classifications, termsGoogle as the only integrative tool
6Copyright Euretos b.v. 2014
![Page 7: Euretos presentation ACS](https://reader036.fdocuments.us/reader036/viewer/2022062406/55baaa87bb61eb744f8b4681/html5/thumbnails/7.jpg)
Market Drivers
Euretos
BRAIN
Use cases
Close
Topics
7Copyright Euretos b.v. 2014
![Page 8: Euretos presentation ACS](https://reader036.fdocuments.us/reader036/viewer/2022062406/55baaa87bb61eb744f8b4681/html5/thumbnails/8.jpg)
Addressing researchers’ needs
8Copyright Euretos b.v. 2014
![Page 9: Euretos presentation ACS](https://reader036.fdocuments.us/reader036/viewer/2022062406/55baaa87bb61eb744f8b4681/html5/thumbnails/9.jpg)
Many online resources
Look through data
Discover new relations
Instantly evaluate evidence
Personalise alerts
Minimise Time to knowledge
Euretos Product Solution:
9Copyright Euretos b.v. 2014
![Page 10: Euretos presentation ACS](https://reader036.fdocuments.us/reader036/viewer/2022062406/55baaa87bb61eb744f8b4681/html5/thumbnails/10.jpg)
Products & Services
10Copyright Euretos b.v. 2014
KaaS
Overview
• Knowledge as a Service• User friendly application• Instant access• Public & private data• Secure• Up to date• Easy collaboration• Alerts
Private Instance
Overview
• On-site BRAIN install• Behind own firewall• Public & private data• Frequent updates• Tailored pricing• Full integration into local
environment
Reports
Overview
• Standard reports• Custom reports
API
Overview
• Access to BRAIN database• Develop own applications
License
• Fixed price per report /• Subscription
License
• Monthly subscription• Integration services
License
• Annual base license &• Per transaction fee
License
• Annual base license &• Support fee &• Professional services
![Page 11: Euretos presentation ACS](https://reader036.fdocuments.us/reader036/viewer/2022062406/55baaa87bb61eb744f8b4681/html5/thumbnails/11.jpg)
Selected references
11Copyright Euretos b.v. 2014
We provide
• BRAIN KaaS to the pre-clinical research team
We provide
• Target dossiers for target owners and internal review panel
We provide
• API for in-house solution development including project support
We provide
• In-house installation of key elements of BRAIN to support data indexing & publishing
KaaS
Overview
• HQ Kopenhagen, DK• Listed company• Development of human
antibody therapeutics for cancer treatment
Private Instance
Overview
• HQ Hinxston, UK• Official EU infrastructure
for life sciences data • ‘FAIR’ datapublishing of
public research data
Reports
Overview
• Based in Leiden, NL• Bayer, Lundbeck, Merck,
AstraZeneca, Janssen, Sanofi, UCB Consortium
• Target screening
API
Overview
• HQ San Diego, US• Agricultural, industrial
and healthcare markets• Plant and yeast genetics
& trait development
![Page 12: Euretos presentation ACS](https://reader036.fdocuments.us/reader036/viewer/2022062406/55baaa87bb61eb744f8b4681/html5/thumbnails/12.jpg)
Market Drivers
Euretos
BRAIN
Use cases
Close
Topics
12Copyright Euretos b.v. 2014
![Page 13: Euretos presentation ACS](https://reader036.fdocuments.us/reader036/viewer/2022062406/55baaa87bb61eb744f8b4681/html5/thumbnails/13.jpg)
A STATEMENT: [Term A - relates to - Term B] & it’s SOURCE
R. Yamaguchi, 2008, Journal of Systems
Biology
Term ‘A’
KLK2 gene
‘relates to’
Causes
Term ‘B’
Prostate Cancer
Source
BRAIN knowledge refinery process
We refine data to the smallest unit of knowledge (a Nanopublication)
Disambiguation – By knowing all terms, their synonyms and storing them as a single concept. Whatever term you enter, we always find what you meanLook through data – By connecting these Nanopublications and thus ‘look through’ all the data sources at onceData reduction – By taking only Nanopublications from raw data and ‘zip up’ all identical ones in a single ‘Cardinal Assertion’. Performance – the result: high performance at a very low footprint
13Copyright Euretos b.v. 2014
![Page 14: Euretos presentation ACS](https://reader036.fdocuments.us/reader036/viewer/2022062406/55baaa87bb61eb744f8b4681/html5/thumbnails/14.jpg)
SEEINGTHROUGH
DATA
Connected
Is inPMID: 22869380 PMID: 22869380
Binds
PMID: 20164304
PMID: 22869380
beta parvin Akt1
BindsPMID: 20164304
paxilin
Leucine aspartic repeat motifs
14Copyright Euretos b.v. 2014
![Page 15: Euretos presentation ACS](https://reader036.fdocuments.us/reader036/viewer/2022062406/55baaa87bb61eb744f8b4681/html5/thumbnails/15.jpg)
Biological pathways
Genetics
Proteins
Phenotypes
Chemical/Pharmacology
Other
H1 2014 H2 2014
Pubmed
Uniprot
ChEMBL
EntrezGene
WikiPW
Drugbank
EnzymeProtein Data bank
Genes /Diseases
Reactome
LOVDENCODESNP db
HMDB
GWAS Jaspar DB TigerEpigenomics
Secreted Protein db
Binding db
DBGaP
BioGRID
SuperLigandsPubChem
NCIClinicaltrial USPTO
GeneOntology
Protein Atlas
CTD
H1 2015
KEGG
Foodb
TD3B
NCI/UMLS
Comprehensive
15Copyright Euretos b.v. 2014
![Page 16: Euretos presentation ACS](https://reader036.fdocuments.us/reader036/viewer/2022062406/55baaa87bb61eb744f8b4681/html5/thumbnails/16.jpg)
In summary: Value to the researcher
First to Knowledge…
Create a single view on private & public dataSee all existing knowledge in all sources at onceDiscover ‘potential’ relationsCollaborate on specific hypothesesKeep up to date via alerts
….First to Market
Find more leads for researchIncrease quality of researchDecrease late stage attrition of leadsAccelerate end to end development processSave time, cost & money
16Copyright Euretos b.v. 2014
![Page 17: Euretos presentation ACS](https://reader036.fdocuments.us/reader036/viewer/2022062406/55baaa87bb61eb744f8b4681/html5/thumbnails/17.jpg)
Market Drivers
Euretos
BRAIN
Use cases – Time to knowledge
Close
Topics
17Copyright Euretos b.v. 2014
![Page 18: Euretos presentation ACS](https://reader036.fdocuments.us/reader036/viewer/2022062406/55baaa87bb61eb744f8b4681/html5/thumbnails/18.jpg)
Based on meticulous reading of 221 articles
Time to knowledge
18Copyright Euretos b.v. 2014
![Page 19: Euretos presentation ACS](https://reader036.fdocuments.us/reader036/viewer/2022062406/55baaa87bb61eb744f8b4681/html5/thumbnails/19.jpg)
Using BRAIN Path predictor function
19Copyright Euretos b.v. 2014
![Page 20: Euretos presentation ACS](https://reader036.fdocuments.us/reader036/viewer/2022062406/55baaa87bb61eb744f8b4681/html5/thumbnails/20.jpg)
Using BRAIN Shortest Path function
20Copyright Euretos b.v. 2014
![Page 21: Euretos presentation ACS](https://reader036.fdocuments.us/reader036/viewer/2022062406/55baaa87bb61eb744f8b4681/html5/thumbnails/21.jpg)
Detail statement and provenance
Not mentioned in the Miedema paper.
21Copyright Euretos b.v. 2014
![Page 22: Euretos presentation ACS](https://reader036.fdocuments.us/reader036/viewer/2022062406/55baaa87bb61eb744f8b4681/html5/thumbnails/22.jpg)
Significant Time-to-Knowledge saving
4 minutes….in BRAINReading 221 papers: WEEKS
22Copyright Euretos b.v. 2014
![Page 23: Euretos presentation ACS](https://reader036.fdocuments.us/reader036/viewer/2022062406/55baaa87bb61eb744f8b4681/html5/thumbnails/23.jpg)
Market Drivers
Euretos
BRAIN
Use cases – Knowledge Prediction
Close
Topics
23Copyright Euretos b.v. 2014
![Page 24: Euretos presentation ACS](https://reader036.fdocuments.us/reader036/viewer/2022062406/55baaa87bb61eb744f8b4681/html5/thumbnails/24.jpg)
“Also just saw this article on ALS and
Retigabine, a drug that affects Potassium
channels and might work for ALS.
Would BRAIN have predicted this relationship?
4Copyright Euretos b.v. 2014
Knowledge prediction
![Page 25: Euretos presentation ACS](https://reader036.fdocuments.us/reader036/viewer/2022062406/55baaa87bb61eb744f8b4681/html5/thumbnails/25.jpg)
Store terms and statements in project folder
5Copyright Euretos b.v. 2014
![Page 26: Euretos presentation ACS](https://reader036.fdocuments.us/reader036/viewer/2022062406/55baaa87bb61eb744f8b4681/html5/thumbnails/26.jpg)
Select statements with relevant relations
6Copyright Euretos b.v. 2014
![Page 27: Euretos presentation ACS](https://reader036.fdocuments.us/reader036/viewer/2022062406/55baaa87bb61eb744f8b4681/html5/thumbnails/27.jpg)
Before this paper was published,
BRAIN contained sufficient indirect
relationships between
Retigabine and ALS to predict it as a potential drug.
7Copyright Euretos b.v. 2014
Discovery that several mutations associated with ALS cause abnormally high activity in motor neurons > early degradation. There is a deficit in open potassium channels in ALS motor neurons. Retigabine, a drug that opens potassium channels and approved for human use, seems to normalize ALS cells in vitro, reducing their hyperexcitability > clinical trials in preparation.
Then visualize statements
Location of
Causes
Stimulates
Interacts with
Causes
Associated with
Location of
Stimulates
Location of
Stimulates
Stimulates
Interacts with Causes
Causes
Location of
Affects
![Page 28: Euretos presentation ACS](https://reader036.fdocuments.us/reader036/viewer/2022062406/55baaa87bb61eb744f8b4681/html5/thumbnails/28.jpg)
Market Drivers
Euretos
BRAIN
Use cases – Target dossier
Close
Topics
28Copyright Euretos b.v. 2014
![Page 29: Euretos presentation ACS](https://reader036.fdocuments.us/reader036/viewer/2022062406/55baaa87bb61eb744f8b4681/html5/thumbnails/29.jpg)
P14735
One click target dossiers
29Copyright Euretos b.v. 2014
We provide
• Target dossiers for target owners and internal review panel
Reports
Overview
• Based in Leiden, NL• Bayer, Lundbeck, Merck,
AstraZeneca, Janssen, Sanofi, UCB Consortium
• Target screening
Key functions
Target – disease association (predict function)
Drugability analysis of a compound
Indepth compound analysis ranked by QeD
![Page 30: Euretos presentation ACS](https://reader036.fdocuments.us/reader036/viewer/2022062406/55baaa87bb61eb744f8b4681/html5/thumbnails/30.jpg)
30Copyright Euretos b.v. 2014
![Page 31: Euretos presentation ACS](https://reader036.fdocuments.us/reader036/viewer/2022062406/55baaa87bb61eb744f8b4681/html5/thumbnails/31.jpg)
31Copyright Euretos b.v. 2014
![Page 32: Euretos presentation ACS](https://reader036.fdocuments.us/reader036/viewer/2022062406/55baaa87bb61eb744f8b4681/html5/thumbnails/32.jpg)
Market Drivers
Euretos
BRAIN
Use cases – Adverse Drug Reaction
Close
Topics
32Copyright Euretos b.v. 2014
![Page 33: Euretos presentation ACS](https://reader036.fdocuments.us/reader036/viewer/2022062406/55baaa87bb61eb744f8b4681/html5/thumbnails/33.jpg)
Adverse drug reaction assessment
33Copyright Euretos b.v. 2013
Rosiglitazone (trade name Avandia, GlaxoSmithKline) is an antidiabetic drug in the thiazolidinedione class of drugs.
A meta-analysis of 16 observational studies released in March, 2011, provides evidence that rosiglitazone is associated with a higher risk of heart failure, myocardial infarction and death than a similar agent, pioglitazone in real life.
![Page 34: Euretos presentation ACS](https://reader036.fdocuments.us/reader036/viewer/2022062406/55baaa87bb61eb744f8b4681/html5/thumbnails/34.jpg)
Connect the key concepts
34Copyright Euretos b.v. 2014
![Page 35: Euretos presentation ACS](https://reader036.fdocuments.us/reader036/viewer/2022062406/55baaa87bb61eb744f8b4681/html5/thumbnails/35.jpg)
Review the evidence
2006
2010
2008
35Copyright Euretos b.v. 2014
![Page 36: Euretos presentation ACS](https://reader036.fdocuments.us/reader036/viewer/2022062406/55baaa87bb61eb744f8b4681/html5/thumbnails/36.jpg)
Market Drivers
Euretos
BRAIN
Use cases
Close
Topics
36Copyright Euretos b.v. 2014